Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Performance

52-Week Range 26.5% below 52-week high

95.49

63.2352W Low 130.0052W High

1 Week

83.691W Low 88.541W High

Mirum Pharmaceuticals, Inc. - common stock (MIRM) traded between $63.23 and $130.00 over the past 52 weeks and last traded at $95.49, 26.5% below its 52-week high. Over the past week it ranged between $83.69 and $88.54.

Past 12 Months

+11.3%

+17.3%

-8.5%

-9.8%

+22.3%

+34.8%

1W +$9.68

1M +$14.06

3M -$8.84

6M -$10.32

YTD +$17.42

1Y +$24.64

MIRM was +34.8% over the past year, -9.8% over six months, +22.3% year to date, +11.3% in the last week.

12 Months vs Market

MIRM

+34.8%

DIA

+12.4%

SPY

+12.4%

QQQ

+10.0%

IWM

+15.6%

Over the past 12 months MIRM returned +34.8% versus DIA (Dow) +12.4%, SPY (S&P 500) +12.4%, QQQ (Nasdaq 100) +10.0% and IWM (Russell 2000) +15.6%.

Volume & Liquidity 0.75× 3-mo avg

Today 545,721 3-mo avg 723.6K

598.6K

721.0K

723.6K

845.0K

YTD

839.2K

819.7K

MIRM most recently traded 545,721 shares against a 3-month average daily volume of 723.6K.

More News

November 03, 2026

Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD’s The Liver Meeting® 2026

November 02, 2026

Mirum Pharmaceuticals (NASDAQ:MIRM) Slides on Wider Loss and Volixibat Delay Despite Revenue Beat ↗

August 05, 2026

Via Chartmill

Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026

October 27, 2026

Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva

October 26, 2026

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

October 21, 2026

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 15, 2026

Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases ↗

October 12, 2026

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

October 12, 2026

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

October 11, 2026

Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study ↗

October 02, 2026

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

September 28, 2026

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026

September 27, 2026

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

September 25, 2026

From Mirum Pharmaceuticals, Inc. and Incyte

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 14, 2026

Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer

September 08, 2026

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

September 02, 2026

Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Via The Motley Fool

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 11, 2026

Mirum Pharmaceuticals Q2 Earnings Call Highlights ↗

August 05, 2026

Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Wondering what's happening in today's after-hours session? ↗

August 05, 2026

Via Chartmill

August 05, 2026

Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

July 29, 2026